Restoration of mutant cytochrome P450 reductase activity by external flavin

Molecular and Cellular Endocrinology

Volumn 321, Issue 2, 2010, Pages 245-252

  Nicolo, Catherine ^a   Flück, Christa E ^a   Mullis, Primus E ^a   Pandey, Amit V ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Antley Bixler syndrome; Cytochrome P450; Cytochrome P450 oxidoreductase; POR; Sex steroids; Steroidogenesis

Indexed keywords

CYTOCHROME B5; CYTOCHROME P450 3A4; CYTOCHROME P450 REDUCTASE; FLAVINE ADENINE NUCLEOTIDE; FLAVINE MONONUCLEOTIDE; STEROID; CYTOCHROME P-450 CYP3A45; CYTOCHROME P450; RIBOFLAVIN DERIVATIVE;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DNA TEMPLATE; DRUG METABOLISM; ENERGY; ENZYME ACTIVITY; ENZYME STRUCTURE; GENE MUTATION; GENETIC VARIABILITY; HUMAN; IN VITRO STUDY; MATHEMATICAL ANALYSIS; MOLECULAR DOCKING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STABILITY; RAT; SEQUENCE ALIGNMENT; STEROID METABOLISM; STRUCTURE ANALYSIS; ANIMAL; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; ENZYME ACTIVATION; GENETICS; METABOLISM; MOLECULAR DYNAMICS; MOLECULAR GENETICS; MOUSE; MUTATION;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME ACTIVATION; FLAVINS; HUMANS; MICE; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; MOLECULAR SEQUENCE DATA; MUTATION; RATS; SEQUENCE ALIGNMENT;

EID: 77951254975     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2010.02.024     Document Type: Article

References (54)

1. Adachi M., Tachibana K., et al. Compound heterozygous mutations of cytochrome P450 oxidoreductase gene (POR) in two patients with Antley-Bixler syndrome. Am. J. Med. Genet. 2004, 128A(4):333-339.
2. Agrawal V., Huang N., et al. Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19. Pharmacogenet. Genomics 2008, 18(7):569-576.
3. Aguilar A., Wu S., et al. P450 oxidoreductase expressed in rat chondrocytes modulates chondrogenesis via cholesterol- and Indian Hedgehog-dependent mechanisms. Endocrinology 2009, 150(6):2732-2739.
4. Arlt W., Walker E.A., et al. Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet 2004, 363(9427):2128-2135.
5. Auchus R.J., Lee T.C., et al. Cytochrome b5 augments the 17,20-lyase activity of human P450c17 without direct electron transfer. J. Biol. Chem. 1998, 273(6):3158-3165.
6. Bartoszek A., Wolf C.R. Enhancement of doxorubicin toxicity following activation by NADPH cytochrome P450 reductase. Biochem. Pharmacol. 1992, 43(7):1449-1457.
7. Bligh H.F., Bartoszek A., et al. Activation of mitomycin C by NADPH:cytochrome P-450 reductase. Cancer Res. 1990, 50(24):7789-7792.
8. Deller S., Sollner S., et al. Characterization of a thermostable NADPH:FMN oxidoreductase from the mesophilic bacterium Bacillus subtilis. Biochemistry 2006, 45(23):7083-7091.
9. Dhir V., Ivison H.E., et al. Differential inhibition of CYP17A1 and CYP21A2 activities by the P450 oxidoreductase mutant A287P. Mol. Endocrinol. 2007, 21(8):1958-1968.
10. Enoch H.G., Strittmatter P. Cytochrome b5 reduction by NADPH-cytochrome P-450 reductase. J. Biol. Chem. 1979, 254(18):8976-8981.
11. Flück C.E., Mullis P.E., et al. Modeling of human P450 oxidoreductase structure by in silico mutagenesis and MD simulation. Mol. Cell. Endocrinol. 2009, 313(1-2):17-22.
12. Flück C.E., Tajima T., et al. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat. Genet. 2004, 36(3):228-230.
13. French J.S., Guengerich F.P., et al. Interactions of cytochrome P-450, NADPH-cytochrome P-450 reductase, phospholipid, and substrate in the reconstituted liver microsomal enzyme system. J. Biol. Chem. 1980, 255(9):4112-4119.
14. Fukami M., Hasegawa T., et al. Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr. Res. 2006, 59(2):276-280.
15. Fukami M., Horikawa R., et al. Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular and clinical studies in 10 patients. J. Clin. Endocrinol. Metab. 2005, 90(1):414-426.
16. Fukami M., Nishimura G., et al. Cytochrome P450 oxidoreductase deficiency: identification and characterization of biallelic mutations and genotype-phenotype correlations in 35 Japanese patients. J. Clin. Endocrinol. Metab. 2009, 94(5):1723-1731.
17. Gillam E.M., Baba T., et al. Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. Arch. Biochem. Biophys. 1993, 305(1):123-131.
18. Gomes A.M., Winter S., et al. Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics 2009, 10(4):579-599.
19. Guengerich F.P. Reduction of cytochrome b5 by NADPH-cytochrome P450 reductase. Arch. Biochem. Biophys. 2005, 440(2):204-211.
20. Gutierrez A., Lian L.Y., et al. Stopped-flow kinetic studies of flavin reduction in human cytochrome P450 reductase and its component domains. Biochemistry 2001, 40(7):1964-1975.
21. Hart S.N., Li Y., et al. Novel SNPs in cytochrome P450 oxidoreductase. Drug Metab. Pharmacokinet. 2007, 22(4):322-326.
22. Hart S.N., Wang S., et al. Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism. Pharmacogenet. Genomics 2008, 18(1):11-24.
23. Huang N., Agrawal V., et al. Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc. Natl. Acad. Sci. U.S.A. 2008, 105(5):1733-1738.
24. Huang N., Pandey A.V., et al. Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am. J. Hum. Genet. 2005, 76(5):729-749.
25. Ilan Z., Ilan R., et al. Evidence for a new physiological role of hepatic NADPH:ferricytochrome (P-450) oxidoreductase. Direct electron input to the microsomal fatty acid chain elongation system. J. Biol. Chem. 1981, 256(19):10066-10072.
26. Ingelman-Sundberg M., Blanck J., et al. Reduction of cytochrome P-450 LM2 by NADPH in reconstituted phospholipid vesicles is dependent on membrane charge. Eur. J. Biochem. 1983, 134(1):157-162.
27. Iyanagi T., Mason H.S. Some properties of hepatic reduced nicotinamide adenine dinucleotide phosphate-cytochrome c reductase. Biochemistry 1973, 12(12):2297-2308.
28. Janner M., Pandey A.V., et al. Clinical and biochemical description of a novel CYP21A2 gene mutation 962_963insA using a new 3D model for the P450c21 protein. Eur. J. Endocrinol. 2006, 155(1):143-151.
29. Johnson M.S., Kuby S.A. Studies on NADH (NADPH)-cytochrome c reductase (FMN-containing) from yeast. Isolation and physicochemical properties of the enzyme from top-fermenting ale yeast. J. Biol. Chem. 1985, 260(22):12341-12350.
30. Kragie L., Turner S.D., et al. Assessing pregnancy risks of azole antifungals using a high throughput aromatase inhibition assay. Endocr. Res. 2002, 28(3):129-140.
31. Kranendonk M., Marohnic C.C., et al. Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley-Bixler syndrome variants of cytochrome P450 oxidoreductase. Arch. Biochem. Biophys. 2008, 475(2):93-99.
32. Krieger E., Darden T., et al. Making optimal use of empirical energy functions: force-field parameterization in crystal space. Proteins 2004, 57(4):678-683.
33. Kurzban G.P., Strobel H.W. Preparation and characterization of FAD-dependent NADPH-cytochrome P-450 reductase. J. Biol. Chem. 1986, 261(17):7824-7830.
34. Marohnic C., Panda S.P., et al. Human cytochrome P450 oxidoreductase deficiency caused by the Y181D mutation: molecular consequences & rescue of defect. Drug Metab. Dispos. 2010, 38(2):332-340.
35. Masters B.S. The journey from NADPH-cytochrome P450 oxidoreductase to nitric oxide synthases. Biochem. Biophys. Res. Commun. 2005, 338(1):507-519.
36. Munro A.W., Noble M.A., et al. Determination of the redox properties of human NADPH-cytochrome P450 reductase. Biochemistry 2001, 40(7):1956-1963.
37. Nadler S.G., Strobel H.W. Identification and characterization of an NADPH-cytochrome P450 reductase derived peptide involved in binding to cytochrome P450. Arch. Biochem. Biophys. 1991, 290(2):277-284.
38. Omura T., Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 1964, 239:2370-2378.
39. Pandey A.V., Joshi S.K., et al. A colorimetric assay for heme in biological samples using 96-well plates. Anal. Biochem. 1999, 268(1):159-161.
40. Pandey A.V., Kempna P., et al. Modulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase. Mol. Endocrinol. 2007, 21(10):2579-2595.
41. Pandey A.V., Mellon S.H., et al. Protein phosphatase 2A and phosphoprotein SET regulate androgen production by P450c17. J. Biol. Chem. 2003, 278(5):2837-2844.
42. Pandey A.V., Miller W.L. Regulation of 17,20 lyase activity by cytochrome b5 and by serine phosphorylation of P450c17. J. Biol. Chem. 2005, 280(14):13265-13271.
43. 2-terminal region on localization in cytosol and membranes. Proc. Natl. Acad. Sci. U.S.A. 1993, 90(7):2651-2655.
44. Ponder J.W., Case D.A. Force fields for protein simulations. Adv. Protein Chem. 2003, 66:27-85.
45. Schacter B.A., Nelson E.B., et al. Immunochemical evidence for an association of heme oxygenase with the microsomal electron transport system. J. Biol. Chem. 1972, 247(11):3601-3607.
46. Schneidman-Duhovny D., Inbar Y., et al. Taking geometry to its edge: fast unbound rigid (and hinge-bent) docking. Proteins 2003, 52(1):107-112.
47. Shen A.L., Porter T.D., et al. Structural analysis of the FMN binding domain of NADPH-cytochrome P-450 oxidoreductase by site-directed mutagenesis. J. Biol. Chem. 1989, 264(13):7584-7589.
48. Shephard E.A., Palmer C.N., et al. Quantification of cytochrome P450 reductase gene expression in human tissues. Arch. Biochem. Biophys. 1992, 294(1):168-172.
49. Sim S.C., Miller W.L., et al. Nomenclature for alleles of the cytochrome P450 oxidoreductase gene. Pharmacogenet. Genomics 2009, 19(7):565-566.
50. Vermilion J.L., Ballou D.P., et al. Separate roles for FMN and FAD in catalysis by liver microsomal NADPH-cytochrome P-450 reductase. J. Biol. Chem. 1981, 256(1):266-277.
51. Vriend G. WHAT IF: a molecular modeling and drug design program. J. Mol. Graphics 1990, 8(1). 52-6, 29.
52. Wang M., Roberts D.L., et al. Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN- and FAD-containing enzymes. Proc. Natl. Acad. Sci. U.S.A. 1997, 94(16):8411-8416.
53. Worth C.L., Bickerton G.R., et al. A structural bioinformatics approach to the analysis of nonsynonymous single nucleotide polymorphisms (nsSNPs) and their relation to disease. J. Bioinform. Comput. Biol. 2007, 5(6):1297-1318.
54. Zhang L.H., Rodriguez H., et al. Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. Proc. Natl. Acad. Sci. U.S.A. 1995, 92(23):10619-10623.